Factors Associated with Serological Cure and the Serofast State of HIV-Negative Patients with Primary, Secondary, Latent, and Tertiary Syphilis

Man-Li Tong1*, Li-Rong Lin1*, Gui-Li Liu1*, Hui-Lin Zhang1, Yan-Li Zeng1, Wei-Hong Zheng3, Li-Li Liu1,2*, Tian-Ci Yang1,2*

1 Center of Clinical Laboratory, Zhongshan Hospital, Medical College of Xiamen University, Xiamen, China, 2 Xiamen Zhongshan Hospital, Fujian Medical University, Xiamen, China, 3 Department of Neurology, Zhongshan Hospital, Medical College of Xiamen University, Xiamen, China

Abstract

Background: Some syphilis patients remain in a serologically active state after the recommended therapy. We currently know too little about the characteristics of this serological response.

Methods: We conducted a cohort study using the clinical database from Zhongshan Hospital, Medical College of Xiamen. In total, 1,327 HIV-negative patients with primary, secondary, latent, and tertiary syphilis were enrolled. Bivariate and multivariate analyses were utilised to identify factors associated with a serological cure and serofast state in syphilis patients one year after therapy. Chi-square tests were used to determine the differences in the serological cure rate across different therapy time points.

Results: One year after the recommended therapy, 870 patients achieved a serological cure, and 457 patients (34.4%) remained in the serofast state. The serological cure rate increased only within the first 6 months. The bivariate analysis indicated that male or younger patients had a higher likelihood of a serological cure than female or older patients. Having a baseline titre $\leq 1:2$ or $\geq 1:64$ was associated with an increased likelihood of a serological cure. The serological cure rate decreased for the different disease stages in the order of primary, secondary, latent, and tertiary syphilis. A distinction should be drawn between early and late syphilis. The multivariate analysis indicated that a serological cure was significantly associated with the disease phase, gender, age, and baseline rapid plasma reagin (RPR) titre.

Conclusions: The serofast state is common in clinical work. After one year of the recommended therapy, quite a few syphilis patients remained RPR positive. The primary endpoint of the study indicated that disease phase, gender, age and baseline RPR titre were crucial factors associated with a serological cure.

Introduction

The World Health Organization describes syphilis as a “sexually transmitted infection that can be successfully controlled by public health measures due to the availability of a highly sensitive diagnostic test and a highly effective and affordable treatment.” Nevertheless, syphilis remains a worldwide public health problem [1–3]. The global syphilis statistics show that an estimated 10 million new infections still occur each year [4]. The rate of congenital syphilis has been increasing in recent years in China, with an average annual increase of 71.9% [5]. Undoubtedly, we are overoptimistic about the prevention of syphilis, and we still know too little about the disease, especially the serological response after therapy [6].

Parenteral penicillin G has been used for more than 50 years, but no comparative trials have been adequately conducted to guide the selection of an optimal penicillin regimen (i.e., the dose, duration, and preparation) [7]. Meanwhile, the basis for evaluating the therapeutic response remains serological testing [7]. Not all patients achieve serological reversal after the recommended treatment, some patients demonstrate a persistent positive serological reaction that was quite disconcerting for both the physician and patient [8]. It remains unclear whether the persistent positive serological reaction indicates persistent foci of spirochetes or progressive syphilitic lesions or whether it reflects the persistence of reagin in the circulating blood following antisyphilitic therapy. For these reasons, a discussion about the
serological response after the recommended therapy is more than justifiable.

Serological tests are the most widely used laboratory techniques for diagnosing syphilis and monitoring its post-treatment course [7]. Serological tests can be divided into two categories: nontreponemal and treponemal antibody tests. The titre of nontreponemal antibodies usually correlates with disease activity, and this titre is the basis for evaluating the therapeutic response [9]. The nontreponemal titre usually decline after therapy. In some patients, nontreponemal antibodies can persist for a long time in a range that differs little from the baseline rapid plasma reagin (RPR) titre after the recommended therapy. These antibodies sometimes persist for the lifetime of the patient. In a previous study, clinical trial data demonstrated that after undergoing the recommended therapy, approximately 15% of patients with early syphilis did not exhibit two-dilution declines or two-dilution increases in the nontreponemal antibody titre. These individuals were considered to be in a “serofast state” one year after treatment [10]. Experience has indicated that, for some patients, the nontreponemal antibody test results remain in a tight range one year after the recommended therapy. This response is called the syphilis serofast state [11–13] or sero-resistance [14].

There is no generally definition of the serofast state (so-called zero-resistance), but most observers agree that the concept should be based on a chosen span of time, amount of treatment and the change of RPR titre [7,14,15]. A fourfold (two dilutions) change in titre is considered necessary to demonstrate a clinically significant difference between two nontreponemal test results that were obtained using the same serologic test [16]. Accordingly, in this study, after one year of recommended therapy, syphilis patients were considered to be in a serofast state if their nontreponemal test remained positive and the titres neither increased nor decreased by at least four-fold (two dilutions). Syphilis patients with persistent or recurrent clinical signs of syphilis and whose nontreponemal antibody titres increased by four-fold or more were considered to exhibit treatment failure or reinfection. Syphilis patients whose clinical manifestations disappeared and whose nontreponemal antibody titres became negative or decreased by four-fold (two dilutions) were regarded as achieving a serological cure. We still know little about the serological response, and the factors that predict the serological response after the recommended therapy among syphilis patients have not yet been thoroughly studied. In our previous study [11,12], we found that Tp-IgM could be used as a serological marker for relapse and syphilis infection. To further explore the characteristics of the serological response, we investigated the factors associated with serological cure and the serofast state in this cohort study.

Methods
Study Population and Ethics Statement
All subjects in the present study were collected from the clinical database of Zhongshan Hospital, Medical College of Xiamen, between June 2005 and May 2010. This study was approved by the Institutional Ethics Committee of Zhongshan Hospital, Medical College of Xiamen University, and was in compliance with the national legislation and the Declaration of Helsinki guidelines. Written patient consent was obtained according to the institutional guidelines.

Serologic Tests
Laboratory analyses, including RPR (InTec Products, Inc., China) and Treponema pallidum particle agglutination (TPPA) (Fujirebio, Tokyo, Japan), were conducted in accordance with the instructions of the manufacturers. All serum samples used in the RPR test were diluted with physiological saline (NaCl 0.9%) at a ratio of 1:1 to 1:32 (V/V) to avoid prozone effects and false-negative results. Readings were taken visually and then compared with the negative and positive controls. The titers of the serum samples that were reactive with RPR were quantified using two-fold serial dilutions until the endpoint was determined. Samples with low titers were randomly and blindly checked by other technicians for quality control. Three standard serum samples with low, medium, and high titers from the National Centers for Clinical Laboratory were used as controls for the RPR reaction. The initial dilution of the serum samples for the TPPA reactions was 1:80.

Testimony of Diagnosis of Syphilis
In the light of CDC guidelines in USA and European [16,17], primary syphilis is characterized by an ulcer (chancre), usually with regional lymphadenopathy, and laboratory confirmation is dark-field examination/fluorescent antibody method/PCR to detect T. pallidum in lesion exudate, or/and a reactive nontreponemal test and a treponemal test to confirm the diagnosis of syphilis. Secondary syphilis is generally characterised by a maculopapular rash, and the laboratory test confirmation is a reactive nontreponemal test and a treponemal test to confirm the diagnosis of syphilis. For Latent syphilis is asymptomatic with a possible history of infection supported by reactive treponemal tests and non-treponemal test and normal cerebrospinal fluid. Tertiary syphilis was defined as syphilis acquired >1 years previously [17], clinical manifestations (i.e., cardiac or gummatous lesions) and a history of primary, secondary, or latent syphilis, moreover, the laboratory test confirmation by reactive nontreponemal and treponemal test.

Syphilis Treatment
Parenterally administered penicillin G is the preferred drug for treating all stages of syphilis [18]. The preparation used (i.e., benzathine, aqueous procaine, or aqueous crystalline), the dosage, and the length of treatment depend on the stage and clinical manifestations of the disease. Generally, non–penicillin-allergic participants underwent treatment randomisation to receive benzathine penicillin (2.4 million U by intramuscular injection for early syphilis or 7.2 million units total, administered at 3 doses of 2.4 million units intramuscular injection each at 1-week intervals for late syphilis). Penicillin allergic participants were randomised to receive doxycycline (100 mg taken orally twice daily for 14 days) or azithromycin (2.0 g daily either IM or IV for 10–14 days) [13]. The detailed recommended therapy schedules for different stages of syphilis strictly followed the CDC’s guidelines. Considering that the type of drug used, the dosage, and the route of administration affected the serological cure. Therefore, only patients treated with penicillin were included in our study. After treatment, patients were advised to undergo serum RPR testing every three months for the first year.

Data Analysis
Statistical analysis was conducted using SPSS version 17.0. Bivariate analysis was utilized to determine the factors associated with the serological cure. The odds ratios (OR) was estimated with 95% confidence intervals (CIs) from the bivariate analysis, and factors with $P$<0.05 were further identified in the multivariate analysis. Adjusted odds ratios (AOR) with 95% confidence intervals (CIs) were also estimated from the regression analysis. Chi-square tests were conducted to identify significant differences across different therapy time points, and $P$<0.05 (two sided) was considered a statistical difference.
Results

Characteristics of the Study Population

A total of 5,460 syphilis patients were found in the Zhongshan Hospital database from June 2005 to May 2010. After excluding the records without documentation of HIV testing and records for HIV-positive or returning patients, 2,707 patients remained. We further excluded patients who did not receive the recommended therapy of penicillin, such as irregular treatment, intermittent treatment, and undertreated therapy. We excluded patients with a false-positive RPR test to avoid the influence on serological response by diseases such as leprosy, systemic lupus erythematosus, HBV, rheumatoid arthritis, thyroid conditions, and respiratory infections. Individuals who were pregnant, experienced treatment failure or reinfection during the course of therapy, had no complement information, or did not agree to participate in our study were also excluded. At last, only 1,327 patients were included into our study sample (Figure 1). The mean age was 41.02 years, and 58.9% were men. In this sample, 31.4% patients had latent syphilis, 22% had primary syphilis, 27.1% had secondary syphilis, and 19.5% had tertiary syphilis. One year after treatment, 65.6% exhibited a serological cure, but 34.4% were serofast (Table 1).

Factors Associated with Serological Response

Our study compared the characteristics of 870 patients who achieved a serological cure with the characteristics of 457 serofast patients at 12 months after therapy. Male patients were approximately 2-fold more likely to achieve a serological cure than female patients. Compared to patients <40 years of age, patients between 23 and 29 years of age had a lower probability of achieving a serological cure, and patients ≥23 years old were comparatively more likely to achieve a serological cure. Patients with lower or higher baseline RPR titres were easily treated and achieved serological cure, but patients with a baseline RPR titre of 1:8 or 1:16 had a decreased likelihood of achieving a cure at 12 months. The serological cure rate for the different disease stages decreased in the order of primary, secondary, latent, and tertiary syphilis (Table 1).

A multivariate analysis was also conducted using all of the significant variables identified above. As shown in Table 2, the results further confirmed that the disease phase, gender, age, and

Figure 1. Patient selection criteria used in this study.
doi:10.1371/journal.pone.0070102.g001
the baseline RPR titre were significantly associated with the likelihood of a serological cure. An age <23 years was associated with a 2-fold greater probability of a serological cure than an age >40 years, and got the highest AOR. Patients with baseline RPR titres of 1:1 and 1:2 had high AORs of 2.732 and 2.380, respectively.

Serological Response at Different Time Points after Therapy

Because the proportion of patients who achieve a serological cure generally increases with time after treatment, the cure rate varied over time. In our research, the serological cure rate was 59.8% (794/1,327) at 3 months and improved to 64.1% (850/1,327) at 6 months. For 6–12 months after treatment, the serological cure rate exhibited a slight increase (from 64.1% to 65.6%), but there were no significant differences among different time points from 6 to 12 months. The serological cure rate did not change substantially with the time after 6 months (Figure 2).

Serological Responses for Different Baseline RPR Titres

The statistical analysis showed that patients with lower or higher baseline RPR titres were more likely to achieve serological cure. Among the 387 patients with baseline RPR titres of 1:1, the proportion who achieved serological cure was approximately 80.1%, and among the 272 patients with baseline RPR titres of ≥1:32, the serological cure rate at 12 months was 60.8%; however, only 49.1% of patients with baseline RPR titres of 1:8 exhibited a serological cure (Figure 3).

Table 1. Bivariate analysis of the characteristics of the patients who achieved serological cure.

| Characteristic      | Serological cure (n = 870) | Serofast (n = 457) | OR     | OR(95% CI) |
|---------------------|---------------------------|--------------------|--------|-----------|
| Low Upper           |                           |                    |        |           |
| Gender              |                           |                    |        |           |
| Female              | 312                       | 233                | 1.000  | 1.000     |
| Male                | 558                       | 224                | 1.860  | 1.478     | 2.341 |
| Age                 |                           |                    |        |           |
| <23                 | 57                        | 13                 | 2.023  | 1.080     | 3.790 |
| 23–29               | 144                       | 113                | 0.588  | 0.434     | 0.796 |
| 30–40               | 281                       | 152                | 0.853  | 0.654     | 1.112 |
| >40                 | 388                       | 179                | 1.000  | 1.000     |       |
| Baseline RPR Titer  |                           |                    |        |           |
| 1:1                 | 310                       | 77                 | 2.984  | 1.979     | 4.498 |
| 1:2                 | 171                       | 73                 | 1.736  | 1.134     | 2.658 |
| 1:4                 | 77                        | 61                 | 0.936  | 0.586     | 1.494 |
| 1:8                 | 55                        | 57                 | 0.715  | 0.437     | 1.171 |
| 1:16                | 77                        | 73                 | 0.782  | 0.495     | 1.234 |
| 1:32                | 95                        | 53                 | 1.329  | 0.832     | 2.122 |
| ≥1:64               | 85                        | 63                 | 1.000  | 1.000     |       |
| Phase               |                           |                    |        |           |
| Primary             | 250                       | 42                 | 1.000  | 1.000     |       |
| Secondary           | 231                       | 129                | 0.298  | 0.195     | 0.453 |
| Tertiary            | 140                       | 119                | 0.196  | 0.126     | 0.305 |
| Latent              | 249                       | 167                | 0.247  | 0.161     | 0.381 |

*Abbreviations: OR, odds ratios; CI, confidence interval.

doi:10.1371/journal.pone.0070102.t001

Table 2. Multivariate analysis of the characteristics of patients who achieved serological cure.

| Parameter         | AOR     | 95.0% C.I. for AOR |
|-------------------|---------|--------------------|
|                   | Lower   | Upper              |
| Secondary VS Primary | 0.372  | 0.244  | 0.568 |
| Tertiary VS Primary | 0.209  | 0.133  | 0.328 |
| Latent VS Primary | 0.341  | 0.223  | 0.522 |
| Female VS Male | 0.594  | 0.460  | 0.767 |
| 1:1 VS ≥1:64 | 2.732  | 1.772  | 4.212 |
| 1:2 VS ≥1:64 | 2.380  | 1.507  | 3.750 |
| 1:4 VS ≥1:64 | 1.438  | 0.871  | 2.374 |
| 1:8 VS ≥1:64 | 0.830  | 0.489  | 1.408 |
| 1:16 VS ≥1:64 | 1.064  | 0.651  | 1.737 |
| 1:32 VS ≥1:64 | 1.617  | 0.990  | 2.642 |
| <23 VS >40 | 2.190  | 1.133  | 4.230 |
| 23–29 VS >40 | 0.564  | 0.401  | 0.794 |
| 30–40 VS >40 | 0.755  | 0.566  | 1.007 |

*Abbreviations: AOR, adjusted odds ratio.

doi:10.1371/journal.pone.0070102.t002
Discussion

Syphilis and Later Syphilis

No significant differences in the serological cure rate from 6 to 12 months; for 6–12 months after treatment, the rate increased over the first 6 months; for 6–12 months after treatment, the proportion of the serological cure over time from 3 to 12 months is shown in Figure 2.

In our study, the prevalence of the serofast state in females was 42.8%, which was higher than that in males. This result was different from the result of a previous study that denied this association [15,27]. Generally, the immune system differs between males and females [28], and the serological response is also influenced by the immune system [19], so gender difference could influence the serological response after treatment. The exact mechanism of this association was still unclear in present research and it needs more detailed investigation. Meanwhile, we found that patients >40 years old had a comparatively lower probability of achieving a serological cure than patients <23 years old. A retrospective analysis found that older age was associated with a lower probability of a serological cure or reduction in the baseline RPR titre [29]. This older population usually demonstrates increasing senescence of the immune system and immunosuppression that would affect the serological response to syphilis therapy [13,15].

Our findings also generally support those of other investigations regarding the relationship between the baseline RPR titre and the serological response [22]. After therapy, the serological cure rate first decreased for titres from 1:1 to 1:8 and then gradually increased as titres increased. A previous study indicated that a high baseline RPR titre signifies a beneficial inflammatory and immune response to therapy, 457 patients remained in a serofast state one year after therapy, 42.8%, which was higher than that in males. This result was different from the result of a previous study that denied this association [15,27]. Generally, the immune system differs between males and females [28], and the serological response is also influenced by the immune system [19], so gender difference could influence the serological response after treatment. The exact mechanism of this association was still unclear in present research and it needs more detailed investigation. Meanwhile, we found that patients >40 years old had a comparatively lower probability of achieving a serological cure than patients <23 years old. A retrospective analysis found that older age was associated with a lower probability of a serological cure or reduction in the baseline RPR titre [29]. This older population usually demonstrates increasing senescence of the immune system and immunosuppression that would affect the serological response to syphilis therapy [13,15].

Our findings also generally support those of other investigations regarding the relationship between the baseline RPR titre and the serological response [22]. After therapy, the serological cure rate first decreased for titres from 1:1 to 1:8 and then gradually increased as titres increased. A previous study indicated that a high baseline RPR titre signifies a beneficial inflammatory and immune response to therapy,

Related Factors of Serological Response

Figure 2. The proportion of the serological cure over time from 3 to 12 months. The proportion of the serological cure rate increased over the first 6 months; for 6–12 months after treatment, the rate increased over the first 6 months; for 6–12 months after treatment, the proportion of the serological cure over time from 3 to 12 months. (χ² = 0.724, P = 0.868).
doi:10.1371/journal.pone.0070102.g002

Figure 3. The proportion of serological cure by baseline RPR titre. The proportion of the serological cure changed with changes in the baseline RPR titre. Overall, the patients with lower or higher baseline RPR titres were more likely to achieve a serological cure (χ² = 74.12, P < 0.001).
doi:10.1371/journal.pone.0070102.g003

What are the factors that influence the likelihood of achieving a serological cure? In this study, using bivariate and multivariate analyses, we found that the disease phase, gender, age, and the baseline RPR titre were associated with a serological cure. The serological cure rate is affected by numerous factors, and we cannot deny the significance of other factors that were not included in the logistic model with multiple variables. A previous study indicated that the type of drug used, the dosage, and the route of administration also affected the serological cure rate [23]. Meanwhile, the relationship between the serofast reaction and neurosyphilis has received a great deal of attention [24]. In our prior study, we analysed the cerebrospinal fluid from 205 patients in the serofast state, 115 of which (56.1%) were diagnosed with neurosyphilis [25]. That study demonstrated the close relationship between the two diseases. Another published study suggested that the serological response was influenced by the body’s immunological function [26].

For many syphilis patients, the serological response varies over time after the recommended therapy. As stated previously, the time point used in the analysis is important when assessing the serological response [15]. Typically, nontreponemal antibody titres should decrease at least fourfold within 6 months after treatment of primary or secondary syphilis and within 12 months after treatment of latent or late infection [21]. In this research, we compared the serological cure rates at different time points after treatment. The results indicate that the proportion of serological cure increased within the first 6 months, but from 6 to 12 months after treatment the serological cure increased only slightly. These findings generally support those of other investigations regarding that the likelihood of a substantial decline in the serofast proportion over time is low. [22]. Considered in this light, it would be appropriate to use a 12-month follow-up standard for syphilis treatment in this research.

In our study, the prevalence of the serofast state in females was 42.8%, which was higher than that in males. This result was different from the result of a previous study that denied this association [15,27]. Generally, the immune system differs between males and females [28], and the serological response is also influenced by the immune system [19], so gender difference could influence the serological response after treatment. The exact mechanism of this association was still unclear in present research and it needs more detailed investigation. Meanwhile, we found that patients >40 years old had a comparatively lower probability of achieving a serological cure than patients <23 years old. A retrospective analysis found that older age was associated with a lower probability of a serological cure or reduction in the baseline RPR titre [29]. This older population usually demonstrates increasing senescence of the immune system and immunosuppression that would affect the serological response to syphilis therapy [13,15].

Our findings also generally support those of other investigations regarding the relationship between the baseline RPR titre and the serological response [22]. After therapy, the serological cure rate first decreased for titres from 1:1 to 1:8 and then gradually increased as titres increased. A previous study indicated that a high baseline RPR titre signifies a beneficial inflammatory and immune response to therapy, 457 patients remained in a serofast state one year after therapy, 42.8%, which was higher than that in males. This result was different from the result of a previous study that denied this association [15,27]. Generally, the immune system differs between males and females [28], and the serological response is also influenced by the immune system [19], so gender difference could influence the serological response after treatment. The exact mechanism of this association was still unclear in present research and it needs more detailed investigation. Meanwhile, we found that patients >40 years old had a comparatively lower probability of achieving a serological cure than patients <23 years old. A retrospective analysis found that older age was associated with a lower probability of a serological cure or reduction in the baseline RPR titre [29]. This older population usually demonstrates increasing senescence of the immune system and immunosuppression that would affect the serological response to syphilis therapy [13,15].

Our findings also generally support those of other investigations regarding the relationship between the baseline RPR titre and the serological response [22]. After therapy, the serological cure rate first decreased for titres from 1:1 to 1:8 and then gradually increased as titres increased. A previous study indicated that a high baseline RPR titre signifies a beneficial inflammatory and immune response to therapy, 457 patients remained in a serofast state one year after therapy, 42.8%, which was higher than that in males. This result was different from the result of a previous study that denied this association [15,27]. Generally, the immune system differs between males and females [28], and the serological response is also influenced by the immune system [19], so gender difference could influence the serological response after treatment. The exact mechanism of this association was still unclear in present research and it needs more detailed investigation. Meanwhile, we found that patients >40 years old had a comparatively lower probability of achieving a serological cure than patients <23 years old. A retrospective analysis found that older age was associated with a lower probability of a serological cure or reduction in the baseline RPR titre [29]. This older population usually demonstrates increasing senescence of the immune system and immunosuppression that would affect the serological response to syphilis therapy [13,15].
response to *Treponema pallidum* (*Tp*), which facilitated the clearance of *Tp* [26]. This observation could be explained by an earlier study [30] that demonstrated VDRL-immunised rabbits exhibited partial protection against reinfection with *Tp*. It is confirmed that HIV significantly influenced the serological response after treatment [31,32]. We did not evaluate the effect of HIV in our study because only 5 HIV-positive patients met our inclusion criteria, and this was not appropriate for statistical analysis.

The influence of the type of syphilitic infection at the beginning of treatment on the serological reaction is an infrequently discussed point [8]. Our results indicated that the serological cure decreased in the order of primary, secondary, latent, and tertiary syphilis. There were 29.3% and 26.2% of patients with early syphilis who did not demonstrate a serological cure at 6 months and 12 months after therapy, respectively. A previous study reported that one-fifth of patients treated for early syphilis did not meet the criteria for serological cure at 6 months after therapy [15]. This difference could be properly explained here. The inclusion criteria for our study population differed from the previous study: returning patients were excluded from our study; every enrolled individual had differences in immunological function that would influence the serological response. Another, we thought the different strains pathogenicity were also a key factor. Some previous studies found that the *Tp* subtypes in different regions were not alike, differing in pathogenicity [33–36]. Some scholars have reported that the *Tp* subtype in China is different from those in other countries [37,38].

Our study has several limitations. The eligible patients represented a fraction of the patients diagnosed with syphilis during the study period, raising a concern for a selection bias. Nearly 38.1% (2,082/5,460) of the patients were excluded because they had not documented HIV test results in our database. Whether the exclusion of these patients affected the outcome is unknown. As a retrospective study, collecting information from medical records previously developed by other professionals is unavoidable but tends to be less accurate. It was difficult to entirely exclude from our research patients with treatment failure or reinfection, which can lead to prolonged seroactivity [19]. The clinical stages of syphilis often overlap, and no concrete indications among the different stages of syphilis exist.

Basic research on serological responses is rare. Our report analyses and discusses the factors associated with a serological cure and the serofast state in syphilis patients after treatment. We hope this discussion proves useful to clinicians and public health workers in identifying patients who may have achieved a serological cure or become serofast, and aids in determining whether serofast patients should undergo a repeated clinical treatment. Given that neurosyphilis is related to the serofast state, cerebral spinal fluid examination should be considered for persons whose nontreponemal antibody titres do not respond appropriately within 6–12 months of therapy or to reinvestigate CSF if the results of a previous examination were normal.

**Acknowledgments**

We thank the patients all for their support in this research and thank the Zhongshan Hospital colleague for their assistance in collection of research data.

**Author Contributions**

Conceived and designed the experiments: TCY LLL MLT LRL GLL. Performed the experiments: MLT GLZ YLZ WHZ. Analyzed the data: TCY LLL LRL. Contributed reagents/materials/analysis tools: MLT HLZ GLL YLZ. Wrote the paper: TCY LLL MLT.

---

**Table 3. Comparison of the responses to therapy between early and late syphilis.**

| Phase | Serological cure (n = 604) | Serofast (n = 286) | OR | P | 95.0% C.I for OR |
|-------|---------------------------|-------------------|----|---|-----------------|
|       |                           |                   |    |   | Lower          | Upper         |
| Late  | 140                       | 119               | 1  |   | 2.391          | <0.001        |
| Early | 481                       | 171               | 3.228 |   | 1.771          |               |

*The serological cure rates of early and late syphilis patients were compared using bivariate analysis. There was a significant difference in the serological cure rate between early and late syphilis patients (P < 0.001). The OR was used to access the serological cure.

doi:10.1371/journal.pone.0070102.t003

---

---

**References**

1. Liu LL, Zheng WH, Tong ML, Liu GL, Zhang HL, et al. (2012) Ischemic stroke as a primary symptom of neurosyphilis among HIV-negative emergency patients. J Neurol Sci 317: 35–39.

2. Ghanem KG, Workowski KA (2011) Management of Adult Syphilis. Clin Infect Dis 53: S110–S128.

3. Dowell D, Polgreen PM, Beekmann SE, Workowski KA, Berman SM, et al. (2009) Dilemmas in the management of syphilis: a survey of infectious diseases experts. Clin Infect Dis 49: 1526.

4. WHO (2011) Global HIV/AIDS response: Epidemic update and health sector progress towards universal access: Progress report. Geneva, Switzerland: World Health Organization.

5. Chea ZQ, Zhang GC, Gong XD, Lin C, Gao X, et al. (2007) Syphilis in China: results of a national surveillance programme. The Lancet 369: 132–138.

6. Rothchild BM (2005) History of syphilis. Clin Infect Dis 40: 1454–1463.

7. Workowski KA, Berman SM (2010) Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 59: 1–110.

8. Moore JE, Padget P (1938) The problem of seroresistant syphilis. Journal of the American Medical Association 110: 96–100.

9. Tsang RSW, Martin IE, Lau A, Sawatzky P (2007) Serological diagnosis of syphilitic comparison of the Trep-Check IgG enzyme immunoassay with other screening and confirmatory tests. FEMS Immunol Med Microbiol 51: 110–124.

10. Rolfs RT, Joesoef R, Hendershot EF, Rompalo AM, Augenbraun MH, et al. (1997) A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. N Engl J Med 337: 307–314.

11. Lin L-R, Zheng W-H, Tong M-L, Fu Z-G, Liu G-L, et al. (2011) Further evaluation of the Characteristics of Treponema Pallidum-specific IgM antibody in syphilis serofast reaction patients. Diagnostic Microbiology and Infectious Disease 71: 201–207.

12. Lin L-R, Tong M-L, Fu Z-G, Dan B, Zheng WH, et al. (2011) Evaluation of a colloidal gold immunochromatography assay in the detection of Treponema pallidum specific IgM antibody in syphilis serofast reaction patients: a serologic marker for the relapse and infection of syphilis. Diagn Microbiol Infect Dis 70: 10–16.

13. Workowski KA, Berman SM (2006) Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 55: 1–94.

14. Higuchi K, Urabe H, Yoshioka M (1961) Some problems on seroresistant syphilis. Kyushu J Med Sci 12: 283–299.

15. Seita AC, Wolff M, Martin DH, Behets F, Van Damme K, et al. (2011) Predictors of serological cure and serofast state after treatment in HIV-negative persons with early syphilis. Clin Infect Dis 53: 1092–1099.

16. CDC. (1998) 1998 guidelines for treatment of sexually transmitted diseases. MMWR Recomm Rep 1998; 47: 1–111.
17. French P, Gomberg M, Janier M, Schmidt B, van Voorst Vader P, et al. (2009) IUSTI: 2008 European guidelines on the management of syphilis. Int J STD AIDS 20: 300–309.
18. Aldave AJ, King JA, Cunningham Jr ET (2001) Ocular syphilis. Curr Opin Ophthalmol 12: 433–441.
19. Ghanem K, Erbelding E, Wiener Z, Rompalo A (2007) Serological response to syphilis treatment in HIV-positive and HIV-negative patients attending sexually transmitted diseases clinics. Sex Transm Infect 83: 97.
20. Yinnon AM, Coury-Doniger P, Pelito R, Reichman RC (1996) Serologic response to treatment of syphilis in patients with HIV infection. Arch Intern Med 156: 321.
21. Romanowski B, Sutherland R, Fick GH, Mooney D, Love EJ (1991) Serologic response to treatment of infectious syphilis. Ann Intern Med 114: 1005–1009.
22. Brown ST, Zaidi A, Larsen SA, Reynolds GH (1985) Serological response to syphilis treatment. JAMA: the journal of the American Medical Association 253: 1296–1299.
23. Chen J (2004) Update on emerging infections: news from the Centers for Disease Control and Prevention. Brief report: azithromycin treatment failures in syphilis infections–San Francisco, California, 2002–2003. Ann Emerg Med 44: 232.
24. Serragui S, Yahyaoui M, Hassar M, Chkili T, Bouhaddioui N, et al. (1999) A comparison study of two therapeutic protocols for neurosyphilis. Therapie 54: 613–621.
25. Li SL LZ, Zhang HS, et al (2012) Relationship between syphilis serofast reaction and neurosyphilis. Chin J Nosocomiol 20: 2235–2238.
26. Salazar JC, Hazelt KRO, Radolf JD (2002) The immune response to infection with Treponema pallidum, the stealth pathogen. Microbes and infection 4: 1133–1140.
27. Hahn RA, Magler LS, Aral SO, Johnson RE, Larsen SA (1989) Race and the prevalence of syphilis seroreactivity in the United States population: a national sero-epidemiologic study. Am J Public Health 79: 467–470.
28. Lahita R (2000) Gender and the immune system. The journal of gender-specific medicine: JGSM: the official journal of the Partnership for Women's Health at Columbia 3: 19.
29. Horberg MA, Ranatunga DK, Quesenberry CP, Klein DB, Silverberg MJ (2010) Syphilis epidemiology and clinical outcomes in HIV-infected and HIV-uninfected patients in Kaiser Permanente Northern California. Sex Transm Dis 37: 53.
30. Baker-Zander SA, Shaifer JM, Lukehart SA (1993) VDRL antibodies enhance phagocytosis of Treponema pallidum by macrophages. J Infect Dis 167: 1100–1105.
31. Tucker JD, Li JZ, Robbins GK, Davis BT, Lobo AM, et al. (2011) Ocular syphilis among HIV-infected patients: a systematic analysis of the literature. Sexually transmitted infections 87: 4–8.
32. Yang C, Latkin C, Luan RS, Wang CL, Nelson K (2010) HIV, syphilis, hepatitis C and risk behaviours among commercial sex male clients in Sichuan province, China. Sexually transmitted infections 86: 539–564.
33. Marra CM, Sahi SK, Tantalo LC, Godomes G, Reid T, et al. (2010) Enhanced molecular typing of Treponema pallidum: geographical distribution of strain types and association with neurosyphilis. J Infect Dis 202: 1380–1388.
34. Florindo C, Reigado V, Gomes J, Azevedo J, Santo I, et al. (2008) Molecular typing of Treponema pallidum clinical strains from Lisbon, Portugal. J Clin Microbiol 46: 3892–3893.
35. Tantalo LC, Lukehart SA, Marra CM (2005) Treponema pallidum strain-specific differences in neuroinvasion and clinical phenotype in a rabbit model. J Infect Dis 191: 75–80.
36. Peng RR, Wang AL, Li J, Tucker JD, Yin YP, et al. (2011) Molecular Typing of Treponema pallidum: A Systematic Review and Meta-Analysis. PLoS neglected tropical diseases 5: 1273–1276.
37. Peng RR, Yin YP, Wei WH, Wang HC, Zhu BY, et al. (2012) Molecular typing of Treponema pallidum causing early syphilis in China: a cross-sectional study. Sex Transm Dis 39: 42–45.
38. Martin IE, Gu W, Yang Y, Tsang RSW (2009) Macrolide resistance and molecular types of Treponema pallidum causing primary syphilis in Shanghai, China. Clin Infect Dis 49: 515–521.